RxDoctor Payments Data

David McDonough, MD

Internal Medicine · Tustin, CANPI 1295866341

Payments from drug & device makers

$4,828in general payments, 2019–2025

Across 142 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$1K
  • Gilead$908
  • Merz North America, Inc.$874
  • Lilly USA, LLC$699
  • Regeneron Healthcare Solutions, Inc.$620
  • Viiv Healthcare Company$278
  • plus $202 from 5 others

What the payments were for

  • Food & beverage$4,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,828 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$20,777
Medicare patients
14
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide349$379,115
SerostimSomatropin17$331,950
BiktarvyBictegrav/Emtricit/Tenofov Ala33$133,611
VascepaIcosapent Ethyl12$4,183
ValacyclovirValacyclovir Hcl27$1,203
Diphenhydramine Hcl17$957
Lidocaine11$791
Omega-3 Acid Ethyl Esters11$665
Armodafinil13$436
Escitalopram Oxalate13$275
Gabapentin30$225
Fluconazole12$218
Propranolol Hcl13$85
Ropinirole Hcl12$77
Allopurinol21$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$699$379,115349 claims
EMD Serono, Inc.Serostim$1,246$331,95017 claims
GileadBiktarvy$908$133,61133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →